Aim: COVID-19 is currently the biggest threat to mankind. Recently, ivermectin (a US FDA-
approved antiparasitic drug) has been explored as an anti-SARS-CoV-2 agent. Herein, we …

Introduction COVID-19 cases are on surge; however, there is no efficient treatment or
vaccine that can be used for its management. Numerous clinical trials are being reviewed for …

The coronavirus disease 2019 (COVID-19) pandemic is a major global threat. With no
effective antiviral drugs, the repurposing of many currently available drugs has been …

SARS-CoV-2 is a newly emerged coronavirus that causes a respiratory disease with
variable severity and fatal consequences. It was first reported in Wuhan and subsequently …

In this study, we have investigated the binding mechanism of two FDA-approved drugs
(ivermectin and levosalbutamol) with the spike protein of SARs-CoV-2 using three different …

Ivermectin (IVM) is a broad-spectrum antiparasitic agent, having inhibitory potential against
wide range of viral infections. It has also been found to hamper SARS-CoV-2 replication in …

Abstract Treatment of SARS-CoV-2 targeting its RNA dependent RNA polymerase (RdRp) is
of current interest. Remdesivir has been approved for the treatment of COVID-19 around the …

Viral infections remain a major cause of economic loss with an unmet need for novel
therapeutic agents. Ivermectin is a putative antiviral compound; the proposed mechanism is …

Utilizing an integrative computational drug discovery approach, we predicted that nelfinavir
is a potential inhibitor of SARS-CoV-2 main protease. Further docking nelfinavir to 30 …

The new coronavirus SARS-COV-2, which emerged in late 2019 from Wuhan city of China
was regarded as causing agent of the COVID-19 pandemic. The primary protease which is …